Neurocrine Biosciences (NBIX) Short term Debt (2018 - 2024)

Neurocrine Biosciences' Short term Debt history runs 6 years deep, the most recent figure standing at $122.8 million for Q1 2024.

• Quarterly Short term Debt changed N/A year-over-year to $122.8 million in Q1 2024, while the trailing twelve-month figure through Mar 2024 was $122.8 million (changed N/A YoY) and the FY2023 annual result came in at $170.1 million, changed 0.41% from the prior year.
• Short term Debt was $122.8 million for Q1 2024 at Neurocrine Biosciences, down from $170.1 million in the prior quarter.
• Across five years, Short term Debt topped out at $425.0 million in Q3 2020 and bottomed at $122.8 million in Q1 2024.
• A 4-year average of $227.0 million and a median of $169.8 million in 2023 frame the typical range for Short term Debt.
• Peak annual rise in Short term Debt reached 0.41% in 2023, while the deepest fall reached 0.41% in 2023.
• Neurocrine Biosciences' Short term Debt stood at $425.0 million in 2020, then tumbled by 60.14% to $169.4 million in 2022, then advanced by 0.41% to $170.1 million in 2023, then retreated by 27.81% to $122.8 million in 2024.
• Business Quant data shows NBIX's Short term Debt at $122.8 million in Q1 2024, $170.1 million in Q4 2023, and $169.9 million in Q3 2023.